China Pharma Holdings, Inc. (CPHI)
NYSEAMERICAN: CPHI · Real-Time Price · USD
0.6650
-0.0036 (-0.54%)
Apr 20, 2026, 4:00 PM EDT - Market closed
China Pharma Holdings Revenue
In the year 2025, China Pharma Holdings had annual revenue of $4.14M, down -8.49%. China Pharma Holdings had revenue of $1.23M in the quarter ending December 31, 2025, with 8.11% growth.
Revenue (ttm)
$4.14M
Revenue Growth
-8.49%
P/S Ratio
6.50
Revenue / Employee
$19,276
Employees
215
Market Cap
26.95M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.14M | -384.66K | -8.49% |
| Dec 31, 2024 | 4.53M | -2.48M | -35.41% |
| Dec 31, 2023 | 7.01M | -1.09M | -13.48% |
| Dec 31, 2022 | 8.10M | -1.54M | -15.95% |
| Dec 31, 2021 | 9.64M | -1.22M | -11.27% |
| Dec 31, 2020 | 10.87M | -57.50K | -0.53% |
| Dec 31, 2019 | 10.92M | -1.41M | -11.41% |
| Dec 31, 2018 | 12.33M | -881.60K | -6.67% |
| Dec 31, 2017 | 13.21M | -2.36M | -15.15% |
| Dec 31, 2016 | 15.57M | -4.78M | -23.49% |
| Dec 31, 2015 | 20.35M | -1.78M | -8.05% |
| Dec 31, 2014 | 22.13M | -10.67M | -32.53% |
| Dec 31, 2013 | 32.81M | -21.70M | -39.81% |
| Dec 31, 2012 | 54.51M | -26.66M | -32.85% |
| Dec 31, 2011 | 81.17M | 6.78M | 9.11% |
| Dec 31, 2010 | 74.39M | 12.69M | 20.57% |
| Dec 31, 2009 | 61.70M | 10.73M | 21.05% |
| Dec 31, 2008 | 50.97M | 17.78M | 53.58% |
| Dec 31, 2007 | 33.19M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| InterCure | 72.16M |
| Rockwell Medical | 69.26M |
| Aytu BioPharma | 62.64M |
| Cumberland Pharmaceuticals | 44.52M |
| Zhengye Biotechnology Holding | 21.46M |
| SCYNEXIS | 20.60M |
| TherapeuticsMD | 3.02M |
| BioXcel Therapeutics | 642.00K |
CPHI News
- 1 year ago - China Pharma Holdings Inc. Announces 1-for-10 Reverse Stock Split - PRNewsWire
- 1 year ago - China Pharma Holdings, Inc. Completes Full Redemptions Under Convertible Note Agreement with Streeterville - PRNewsWire
- 1 year ago - China Pharma Announces the Entry of "At-The-Market" Equity Offering - PRNewsWire
- 1 year ago - China Pharma Holdings, Inc. expects to launch its Dry Eye Disease Therapeutic Device in the first quarter of 2025 - PRNewsWire
- 2 years ago - China Pharma Holdings Inc. Announces 1-for-5 Reverse Stock Split - PRNewsWire
- 2 years ago - China Pharma Holdings, Inc. Announced the Completion of Third Party Testing of Dry Eye Disease Therapeutic Device - PRNewsWire
- 2 years ago - China Pharma's Candesartan Hypertension Product Passes the Quality and Efficacy Consistency Evaluation of Generic Drugs - PRNewsWire
- 3 years ago - China Pharma Holdings, Inc. Announced the Launch of N95 Medical Protective Mask - PRNewsWire